Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.

Abstract

Forty-six eligible women with metastatic endometrial cancer were randomly allocated to receive monthly cycles of either CAF (cyclophosphamide, adriamycin, 5-fluorouracil) or CAF plus Provera 200 mg daily for 3 weeks followed cyclically by Tamoxifen 20 mg daily for 3 weeks. Overall response rates of 15 and 43% were seen with CAF and CAF plus hormonal therapy. Using a multivariate analysis of the results, this difference is significant (P value 0.05). In 8 patients with operable endometrial cancer, negative estrogen receptor concentration (ER less than 15 fmole/mg protein) and Grade 3 disease, the clinical course was aggressive in 4 patients with systemic and local relapse. In 10 other similar patients (negative ER and Grade 3) who received adjuvant cyclical hormonal therapy only 1 relapsed and the other 9 are disease-free for an average of more than 31 months. Sequential cyclical hormonal therapy with ER and progesterone receptor analysis has a place in the management of endometrial carcinoma.

• Authors: J Ayoub, P Audet-Lapointe, Y Méthot, J Hanley, R Beaulieu, R Chemaly, A Cormier, J P Déry, P Drouin, P Gauthier
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 31 Issue 2 Pg. 327-37 (Oct 1988) ISSN: 0090-8258 [Print] United States
• PMID: 2971597 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Estrogen
• Receptors, Progesterone
• Tamoxifen
• Doxorubicin
• Cyclophosphamide
• Medroxyprogesterone Acetate
• Medroxyprogesterone
• Fluorouracil

Topics

• Adenocarcinoma (analysis, drug therapy, pathology, radiotherapy)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Cyclophosphamide (administration & dosage)
• Doxorubicin (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Humans
• Medroxyprogesterone (analogs & derivatives, therapeutic use)
• Medroxyprogesterone Acetate
• Middle Aged
• Multicenter Studies as Topic
• Neoplasm Recurrence, Local (drug therapy)
• Prospective Studies
• Random Allocation
• Receptors, Estrogen (analysis)
• Receptors, Progesterone (analysis)
• Remission Induction
• Tamoxifen (therapeutic use)
• Uterine Neoplasms (analysis, drug therapy, pathology, radiotherapy)